DexCom reports Q4 EPS 45c, consensus 50c

Reports Q4 revenue $1.11B, consensus $1.10B. “In 2024, we implemented our largest US commercial sales force expansion, had two major product launches with Dexcom (DXCM) One+ and Stelo and submitted our G7 15-day product to the FDA,” said Kevin Sayer, Dexcom’s chairman, president and CEO. “As we enter 2025, we look forward to building on these investments as we unlock the next wave of access to Dexcom CGM globally.”